the incidence and impact of anti-human leukocyte antigen donor-specific alloantibodies (DSas) developing after liver transplantation (lt) remains controversial and not extensively studied. the aim of the present study was to assess the incidence of DSas, to identify risk factors for the development of DSas, and to understand the impact of DSas in a large population of adult lt recipients. this single-center retrospective study included all adult patients who underwent a first lt between 2000 and 2010 in our center. the study population mainly consisted of male patients, the mean age was 52.4 years, and the main indication was alcoholic cirrhosis (54.1%). From the 297 patients included in the cross-sectional study, 14 (4.7%) had preformed DSas, and 59 (19.9%) presented de novo DSas (12.2% at 1 year, 13.4% at 5 years, and 19.5% at 10 years). Multivariate analysis found that female donor sex (hazard ratio [Hr], 1.50; 95% confidence interval [ci], 1.12-2.01; P = 0.01) and delay between lt and DSa screening (Hr, 1.10; 95% ci, 1.01-1.20; P = 0.03) were associated with occurrence of de novo DSas. From the 190 patients included in the subgroup longitudinal analysis, exposure to tacrolimus (mean trough level during the periods 0-2 years and 0-3 years) was significantly lower for patients having DSas at 5 years. concerning histology, only acute rejection (P = 0.04) and portal fibrosis ≥2 (P = 0.02) were more frequent at 1 year for patients with DSas. Patient survival and graft survival were not significantly different according to the presence or not of DSas at 1 year. among the 44 patients who had de novo or persistent preformed DSas, the diagnosis of antibody-mediated rejection was made in 4 (9.1%) patients after 1, 47, 61, and 74 months following lt. in conclusion, the results of the present study suggest that DSas are observed in a minority of lt adult patients, with limited overall impact on graft and patient outcome.
Since the initial description by Patel and Terasaki in 1969, (1) cytotoxic anti-human leukocyte antigen (HLA) antibodies are known to be associated with graft rejection in kidney transplantation. Techniques for detection of HLA antibodies have become more sensitive, and it is now widely accepted that patients with anti-HLA donor-specific alloantibodies (DSAs) are susceptible to develop different forms of antibody-mediated rejection (AMR; or humoral rejection) because of chronic inflammation and progressive tissue destruction. AMR is now widely recognized as a major cause of late kidney graft loss. (2, 3) In addition, the negative impact of preformed or de novo DSAs is now also widely agreed in pancreas, (4) lung, (5) heart, (6) and intestinal (7) transplant recipients. Historically, liver has been considered as a less sensitive organ to AMR. The first observation of AMR was reported in 1988 after an ABO-incompatible liver transplantation (LT). (8) Thereafter, preformed or de novo DSAs in ABO-compatible (ABOc) LT have been associated with graft loss, chronic rejection, acute AMR, graft fibrosis, and/or death. (9) (10) (11) (12) (13) (14) (15) (16) (17) The aim of the present study was to assess the incidence of DSAs, identify risk factors for the development of DSAs, and evaluate the impact of DSAs on patient and graft survival in a large population of adult LT recipients with longterm follow-up.
Patients and Methods

StUDY DeSiGn
The present single-center retrospective study included all adult patients who underwent a first LT between January 2000 and September 2010 at the Edouard Herriot University Hospital (Lyon, France) and who had both at least 1 screening for anti-HLA antibodies at day of transplantation (day 0) and another screening after LT. A subgroup analysis focused on all patients who underwent a LT between January 2005 and September 2010, who had longitudinal screening for anti-HLA antibodies, at day 0, and 1, 5, and/or 10 years thereafter, together with biological and histological protocolized follow-up. Patients with combined (liver-kidney, liver-heart) transplantation were not included. All transplantations were ABOc LT. The study protocol was approved by our local hospital review committee.
The initial immunosuppressive regimen was based on calcineurin inhibitors: cyclosporine or tacrolimus. In addition, patients received 500 mg of methylprednisolone after reperfusion. Induction with polyclonal or monoclonal antibodies was performed in some liver-kidney recipients and in cases of renal failure at the time of the LT for delayed calcineurin inhibitor introduction. On postoperative day 1, we began tapering methylprednisolone, which was maintained at 20 mg/day thereafter, then tapered by 2.5 mg/month to a maintenance dose of 0-5 mg/day after 12 months after transplantation. Azathioprine (1990 Azathioprine ( -1996 or mycophenolate mofetil (MMF; since 1996) was eventually administered as part of an initial triple immunosuppressive regimen.
Screening was performed retrospectively on historical serum samples for the anti-HLA antibodies before 2010, and prospectively after 2010. DSAs were considered as de novo when not present at day 0. Timing between LT and DSA screening was calculated as the interval between transplantation, and either the last negative DSA screening or the first positive DSA screening. Concerning DSA screening from historical serum, it was usually performed at 1, 5, and 10 years protocolized evaluation after transplantation (serum was obtained from our virology department).
Liver function tests (LFTs)-serum aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase (GGT), alkaline phosphatase, total bilirubin, direct bilirubin, and indirect bilirubin-and measurement of immunosuppressive drug blood levels were performed by the hospital's laboratory during hospitalizations and externally before routine patient visits.
Exposure to tacrolimus was estimated as the mean trough level of the drug. It was calculated from measurements at postoperative days 3, 7, 14, and 30, at postoperative months 3, 6, 9, and 12, and then annually. (18) Protocol liver biopsies were planned at 1, 5, and 10 years from transplantation. All biopsies performed for LFT abnormalities and protocol biopsies were reviewed. For diagnosis and grading of allograft rejection, the Banff classification published in 1997 and updated in 2000 was used. (19) Portal fibrosis was graded according to the METAVIR score, (20) and centrilobular fibrosis was graded using a modification of the nonalcoholic fatty liver disease staging system devised by the pathology committee of the Nonalcoholic Steatohepatitis Clinical Research Network, (21) reported by MiyagawaHayashino et al. (22) All liver biopsies with features of rejection were reviewed, and the histological diagnosis of AMR, including complement component 4d staining, was made from the Banff update of 2016. (23) To identify risk factors for DSAs and their impact, the DSA-positive and DSA-negative populations were compared with regards to demographic, clinical, histological, and biochemical data.
iMMUnOlOGiCAl AnAlYSeS
All analyses were performed in a blinded fashion by a trained immunobiologist (V.D. at the Etablissement Français du Sang, Lyon, France). HLA typing of donors and recipients was performed by PCR-SSO reverse (One Lambda, Canoga Park, CA). Serum samples were analyzed using Single Antigen Flow Beads assays
Original article | 1093 (Lifecodes Single Antigen [LSA] class I and class II, Lifecodes, Immucor, Norcross, GA). The mean fluorescence intensity (MFI) was measured on a LABscan IS 200, and all the specificities were evaluated with the company's defined threshold such as MFI ≥ 1500 and MFI adjusted to the quantity of coated antigen per bead (AD-BCR) ≥5 to define positivity (AD-BCR is a ratio of adjusted MFI to the quantity of coated antigen per bead). The positivity of these 2 criteria together allows us to consider the corresponding specificities as a preformed DSA. In a few cases, only the AD-BCR is higher than 5, with MFI between 500 and 1500. In these cases, the DSA is validated only for posttransplantation follow-up (de novo DSA) when the corresponding graft mismatch antigen is not included in a Cross-Reactive group (CREg)-positive reaction.
StAtiStiCAl AnAlYSeS
Categorical variables were expressed as percentages and compared with the chi-square or Fisher' s exact tests. Continuous variables were expressed as mean ± standard deviation (SD) and compared using the Student t test or the MannWhitney U test in the case of non-Gaussian distributions. Patient survival was calculated from the date of LT to that of death or the final clinical visit. Graft survival was calculated from the date of LT to that of retransplantation, death, or last visit if there was no retransplantation. Survival curves were constructed using the Kaplan-Meier method and compared with the log-rank test. Cox proportional hazards regression was used in both univariate and multivariate models. All significant variables in the univariate analysis with a level set at P < 0.1 were incorporated into the multivariate model. A P value < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS software, version 13.0 (IBM, Armonk, NY).
results
CROSS-SeCtiOnAl StUDY
Study Population
During the 2000-2010 period, 480 patients underwent a first LT at our center. Among these, 437 survived at least 6 months after transplantation, of whom 356 were screened for anti-HLA antibodies on the day of transplantation, and 297 also had at least 1 other screening after LT and were included in a cross-sectional study. Of those included, 14 (4.7%) had preformed DSAs (from 1 to 5 DSAs in class I, with MFI from 1600 to 17,000; from 1 to 4 DSAs per patient in class II, with MFI from 1500 to 19,400), 5 (1.7%) had persistent preformed DSAs, and 59 (19.9%) had de novo DSAs after LT: 20/164 (12.2%) at 1 year, 29/217 (13.4%) at 5 years, and 26/133 (19.5%) at 10 years ( Fig.  1) . Among patients who survived less than 6 months and who had an antibody screening at day of transplantation (n = 36), 2 (5.5%) had preformed DSAs. Causes of early post-LT death (n = 43) included sepsis (n = 24, 55.8%), multiorgan failure (n = 8, 18.6%), cardiovascular disease (n = 5, 11.6%), neurological disease (n = 4, 9.3%), primary nonfunction (n = 1, 2.7%), and acute rejection (n = 1, 2.3%). The patient who died from acute rejection had no DSAs.
Most de novo DSAs were anti-class II alone (91.5%) and anti-DQ for 69.5%. Preformed DSAs were mostly a combination of anti-class I and anti-class II DSAs (6/14, 42.9%). All persistent preformed DSAs were class II alone. Median maximal MFI was 10,700 (1900-19,400) for preformed DSAs which persist after transplantation, and 7700 (600-17,500) for de novo DSAs (Table 1) . When considering DSAs with MFI 3000 as high MFI DSAs, the cohort included 5 patients with persistent preformed high MFI DSAs and 42 patients with de novo high MFI DSAs (Table 1) .
Risk Factors for DSAs
The study population mainly consisted of male patients, the mean age was 52.4 years, and the main indication was alcoholic cirrhosis, with or without HCC (54.1%). The initial immunosuppressive therapy consisted mostly of tacrolimus (95.2%), MMF (72.6%), and steroids (99.3%). The variables that were significantly associated with the presence of de novo DSAs were the donor female sex (P = 0.01), recipient/donor sex mismatch (P = 0.02), and the interval between LT and DSA screening (P = 0.02). Recipient sex, etiology of initial liver disease, initial immunosuppressive therapy, or number of rejection episodes were not associated with the presence of de novo DSAs (Table 2) .
Because donor female sex and recipient/donor sex mismatch (man/woman) are not independent, 2 multivariate models were built. In the first multivariate model, factors associated with post-LT DSAs were female donor sex (hazard ratio [HR], 1.50; 95% confidence interval [CI], 1.12-2.01; P = 0.01) and the interval between LT and DSA screening (HR, 1.10; 95% CI, 1.01-1.20; P = 0.03). In the second multivariate model, the recipient man/donor woman mismatch was NOTES: Values are given from the entire cohort (n = 297). Data are given as n (%) or median (range). *Among those concerned. **Maximal cumulative MFI. 
Survival
Patient survival and graft survival were not different according to the presence of DSAs. tacrolimus exposure effect Table 3 summarizes the prevalence of DSAs, at different time points, according to the mean exposure to tacrolimus. Mean levels 0-2 years and 0-3 years were significantly lower for patients having DSAs. When considering only DSAs with high MFI (n = 19) versus the others (n = 114), only mean tacrolimus level 0-3 years was significantly lower for patients with DSAs (5.7 ± 1.8 versus 6.7 ± 1.8 ng/mL; P = 0.037). The use of MMF as maintenance immunosuppression (IS) therapy had no significant impact. Table 4 summarizes the impact of DSAs at 1, 5, and 10 years on LFTs and histological lesions at the same time point. The presence of DSAs had no significant impact on LFTs, at any time point. Concerning histology, acute rejection was significantly more frequent at 1 year for patients presenting DSAs at that date (P = 0.04) as portal fibrosis ≥ 2 (P = 0.02). There was a trend toward more frequent fibrosis stage ≥ 3 among patients with DSAs at 5 years (P = 0.06).
SUBGROUP lOnGitUDinAl AnAlYSiS Study Population
Biological and Histological effect
Antibody-Mediated Rejection
Among the 44 patients who had de novo or persistent preformed DSAs, the diagnosis of AMR was made in 4 (9.1%) patients, after 1, 47, 61, and 74 months following LT. These patients had class II DSAs, with MFI ranging from 1500-28,600, and liver graft dysfunction. Treatment consisted of steroids, rituximab, plasmapheresis, and immunoglobulins. One patient died 13 months after diagnosis and the other 3 improved (with a follow-up of 30, 46, and 70 months). DSAs disappeared in 2 patients with favorable outcomes, and maintenance immunoglobulins were discontinued.
Survival
According to Kaplan-Meier estimates, patient and graft survivals were not significantly different according to the presence or not of DSAs at 1 year ( Fig. 2A,B) . Similarly, according to the presence of high MFI DSAs, patient and graft survivals were similar (Fig. 2C,D) . In addition, patient and graft survivals were not significantly different according to the presence or not of DSAs, starting at the date of the first DSA screening (data not shown).
Discussion
Over the last decade, our knowledge on DSAs in LT recipients has dramatically changed, and now DSAs are no longer considered to be clinically irrelevant to LT outcome. Nevertheless, the present retrospective study adds comprehensive data to this field and finds Original article | 1097 NOTE: Data are given as n (%).
that DSAs have little meaningful impact on hepatic transplant. Herein, DSAs were found to be rare, which is in accordance with the literature, yet it is of note that preformed DSAs were relatively infrequent as compared with previous reports. For instance, in LT recipients, Taner et al. reported from a small cohort of 90 LT recipients that 22.2% of patients had preformed DSAs with an MFI ≥ 2000, that disappeared thereafter for 85% of them. (24) Similarly, 14% of 1270 LT recipients had preformed DSAs with a mean MFI ≥ 5000 in the study reported by O'Leary et al. (13) that remained persistent in 5% for preformed class I DSAs with an MFI ≥ 5000; 23% for preformed class II DSAs with an MFI of 5000-10,000; and 33% for preformed class II DSAs whose MFI was ≥10,000. (13) This difference in preformed DSAs is likely to be due to differences in study populations, especially regarding etiology of liver disease, that was mostly hepatitis C in these studies (probably in relation to the more frequent history of transfusion and a greater proportion of women with a history of pregnancy), whereas alcoholic cirrhosis was the main indication in our center (and in French centers in general). Concerning de novo DSAs, despite differences in the threshold of MFI used, the incidence herein was quite similar to that found elsewhere (a fifth of patients presented de novo DSAs, mostly anti-DQ) when the duration of follow-up is taken into consideration. For instance, Kaneku et al. reported a 1-year incidence of de novo DSAs (with an MFI ≥ 5000) of 8.1% among a cohort of 749 LT recipients. Antibodies were mostly directed against anti-class II antigens (anti-DQ locus for 85%). (11) In the French cross-sectional study reported by Del Bello et al., 14% of 152 patients developed de novo DSAs (with an MFI ≥ 1000) with a median (range) follow-up of 34 (1.5-77) months, directed against anti-class II antigens for 86%. (16) In another article, the same authors report that 13.1% of 267 patients had at least 1 DSA (with an MFI ≥ 1000) at a median (range) of 51 (6-220) months after transplantation, and that the incidence of de novo DSAs was variable according to the time since transplantation (0% for 6-12 months, 10% for 1-3 years, 5% for 3-5 years, and 11.2% for >5 years). (17) With regards to factors associated with DSAs, Kaneku et al. reported that the use of cyclosporine (odds ratio [OR], 2.50; P = 0.004) and low doses of calcineurin inhibitors (OR, 2.66; P = 0.015) were risk factors for occurrence of DSAs, whereas a Model for End-Stage Liver Disease score of >15 at transplantation 
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(OR, 0.47; P = 0.021) and a recipient age of more than 60 years (OR, 0.26; P = 0.03) were protective factors. (11) Del Bello et al. found that lower exposure to calcineurin inhibitors and younger age of recipients were associated with DSAs. (16) Interestingly, mean trough levels of tacrolimus (0-2 years and 0-3 years) were significantly lower for patients who developed DSAs (even if the magnitude of the difference in tacrolimus level is small). In addition, these results need to be interpreted with caution because lower levels could be intentional or due to noncompliance. Nevertheless, the level of IS seems to play a role in the formation of de novo DSAs, but probably over the long term. In addition, it was also found in the present study that female donor sex (or recipient man/ donor woman mismatch) and the interval between LT and DSA screening were associated with DSAs. We do not have a relevant hypothesis to explain the former. Interestingly, female recipients were not at an increased risk for de novo DSAs. The latter could be explained by a reduction of IS over time or by nonadherence. However, it is of note that the initial IS regimen was not a risk factor for development of DSAs herein, but IS was near uniform in the population because only 12 patients received cyclosporine. Finally, nonadherence would need to be investigated. Unfortunately, we do not have a robust evaluation of adherence in our clinical charts.
At the present stage of our knowledge, the major open question is undoubtedly the impact of DSAs on liver graft function. Taner et al. evaluated the impact of preformed DSAs and found no difference in patient and graft survival rates between patients with or without DSAs. (24) O'Leary et al. found that persistent preformed class-II DSAs with a MFI ≥ 5000 were independent factors for early rejection (HR, 1.58; P = 0.004). (13) Musat et al. found an association between preformed DSAs and acute cellular rejection (anti-class I-HR, 2.7; P < 0.01; anti-class II-HR, 6; P < 0.01), regardless of the level of MFI, even though a MFI ≥ 1000 gave the best predictive value of clinically significant acute cellular rejection. (12) Concerning de novo DSAs, 9 of the 21 (43%) patients who developed these presented acute AMR (P = 0.005) in the study reported by Del Bello et al., but patient and graft survival rates did not differ between those with and without DSAs, (16) whereas Kaneku et al. found that patients with de novo DSAs at 1 year had significantly lower overall survival (P = 0.002) and graft survival (P = 0.005). (11) In the study reported by O'Leary et al., de novo DSAs were more often detectable in patients who had chronic rejection than in controls (62% versus 38%; P = 0.047). (10) The same authors also reported, from 749 patients without preformed DSAs, that formation of de novo DSAs led to a higher risk of death (HR, 1.8; P = 0.007). (15) Herein, the clinical impact of DSAs was less impressive because LFTs and patient and graft survival were not different between patients with and without DSAs, and only some histological lesions (acute rejection and portal fibrosis ≥ 2 at 1 year) were more frequent among those with DSAs. It is important to note, however, that some cases of AMR have been reported in the different published reports, for example, 9/21 patients with DSAs for Del Bello et al., 4/44 in the present study, which highlights that a minority of these patients can undoubtedly develop severe graft injury. LT strongly differs from kidney or heart transplantation because graft losses are very limited and patient survival is highly impacted by nonimmunological complications of transplantation (especially de novo cancers in patients with history of alcoholic cirrhosis). Nevertheless, it has been suggested that recurrence of hepatitis on liver graft could be more severe in the presence of DSAs. (25) This could have a major impact in cohorts with predominantly hepatitis C virus-related initial disease, which is not the case in the present study.
In order to investigate the pathogenic potential of DSAs and to better identify patients at high risk for kidney-allograft loss, Loupy et al. used the evaluation of DSA capacity to bind complement fraction C1q, (26) and Sicard et al. the ability to bind C3d, at the time of AMR diagnosis. (27) Recently, Del Bello et al. investigated the C1q-binding ability of de novo DSAs in LT patients; 22% of DSAs were able to bind C1q, and some patients who developed AMR were C1q negative. (16) We will investigate this point in a larger population in the near future because we recently reported that C3d-binding DSAs could be helpful for the diagnosis and treatment monitoring of AMR in 3 of our patients. (28) In addition, we also reported the deleterious impact of C3d-binding DSAs in pediatric LT recipients. (29) Another point to consider is the DSA immunoglobulin G (IgG) subclasses because it has been reported that IgG3 DSAs were more frequently observed in patients with chronic rejection and graft loss. (15, 30) Our study undoubtedly has some limitations related to its retrospective design, the relatively small number of patients, and the heterogeneous immunosuppressive regimens used over a long period of time. In the absence of recommendations and according to variability between manufacturers, we chose a low cutoff of MFI for de novo DSAs in order to increase sensitivity, regarding the low rate of DSA positivity. Nevertheless, only 2 of our patients had MFI < 1500 DSAs after LT, and focused analysis on DSAs with high MFI disclosed similar results than in the entire population.
In conclusion, our results suggest that the incidence of DSAs, and especially de novo DSAs, is rare in adult LT patients, with limited overall impact on graft and patient outcome. Nevertheless, DSAs can have deleterious consequences in some individuals, and this needs to be further investigated.
